Immune drugs given before surgery show promise against multiple cancers
NCT ID NCT03916627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before their planned surgery. The main goal is to see how well the tumor responds and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab (also known as Libtayo), sometimes combined with fianlimab or platinum chemotherapy
- What this could lead to
- If successful, this could show that giving these immune-boosting drugs before surgery helps shrink tumors and improve outcomes for people with these cancers.
- What could go wrong
- This is a small, early-phase study (65 people) across three cancer types, so results may not apply broadly. Side effects from immune activation can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Could a vaccine help fight Hard-to-Treat cancers?